FDA requires label change for Yaz/Yasmin/Ocella (drospirenone-containing birth control)

The FDA just completed its review of various studies and has concluded that women taking drospirenone-containing birth control pills (such as Yaz, Yasmin or Ocella) may have a higher risk of developing blood clots (such as deep vein thrombosis and/or pulmonary embolisms) than women taking progestin-containing birth control pills….as much as THREE TIMES THE RISK.

Click on this link to read the actual FDA warning: FDA Warning Regarding Drospirenone-containing Birth Control

What is Drospirenone?

Drospirenone is a synthetic version of progesterone (also known as progestin), which is a female hormone.  In combination with ethinyl estradiol, it is used as contraception, to treat moderate acne, and to treat premenstrual dysphoric disorder.


Required Label Change

The FDA is now requiring manufacturers of drospirenone-containing birth control pills to revise their labels to include the fact that some studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products, as opposed to birth control pills that contain levonorgestrel or some other progestins. The labels will also state, however, that some of the studies showed no increased risk of blood clots with drospirenone-containing products. 

If you have taken Yaz, Yasmin or Ocella and have developed blood clots, call Kogan & Associates immediately at 800-876-2303 to discuss potential compensation.